Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
…
PHASE III EFFICACY RESULTS OF INVESTIGATIONAL MEDICINE OCREVUS™ (OCRELIZUMAB) REINFORCED BY EXPLORATORY ANALYSES IN TWO FORMS OF MULTIPLE SCLEROSIS
…
Stuart Schlossman
Multiple Sclerosis: More Good News on Siponimod
…
Stuart Schlossman
Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets
…
Stuart Schlossman
1st Generic for Copaxone to Treat Relapsing MS Available in Central and Eastern Europe
…
Stuart Schlossman
Managing MS Day-to-Day
…
Stuart Schlossman
MAKE your Voice HEARD on MS Treatments
…
Stuart Schlossman
Neurologists Report Increasing Payer (Insurer) Pressure For Disease-Modifying Therapies, Resulting In Suboptimal Treatment For Some Patients With Multiple Sclerosis
…
Stuart Schlossman
The oncology molecule’s launch offers a new hope for Multiple Sclerosis patients
…
Stuart Schlossman
Novartis (NVS) Reports Positive Phase III Results on MS Drug
…
Stuart Schlossman
